Pilot: Impact of High-Dose, Single Fraction Radiation on Immunogenicity of Sipuleucel-T in Metastatic Castration Recurrent Prostate Cancer Patients
Phase of Trial: Phase I
Latest Information Update: 27 Apr 2017
At a glance
- Drugs Sipuleucel-T (Primary)
- Indications Prostate cancer
- Focus Pharmacodynamics; Pharmacogenomic
- 07 Jun 2017 Biomarkers information updated
- 24 Apr 2017 Planned End Date changed from 1 Dec 2015 to 5 Dec 2018.
- 09 Feb 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017 according to ClinicalTrials.gov record.